Twist Bioscience Corporation (TWST) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2022-09-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2022-09-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2022-09-30..
Borrowing debt
Overview →Financial period ending 2022-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2022-09-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2022-09-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2022-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 961.38M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | $961.38M | (m) |
| 2022-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | $979.66M | (m) |
| 2022-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | $1.02B | (m) |
| 2021-09-30 | (m) | (m) | $1.55M | (m) | (m) | (m) | $702.10M | (m) |
| 2021-06-30 | (m) | (m) | $2.37M | (m) | (m) | (m) | $725.30M | (m) |
| 2021-03-31 | (m) | (m) | $3.17M | (m) | (m) | (m) | $677.29M | (m) |
| 2020-12-31 | (m) | (m) | $3.33M | $625.00K | (m) | (m) | $699.57M | (m) |
| 2020-09-30 | (m) | (m) | $3.33M | $1.40M | (m) | (m) | $398.88M | (m) |
| 2020-06-30 | (m) | (m) | $3.33M | $2.17M | (m) | (m) | $408.24M | (m) |
| 2020-03-31 | (m) | (m) | $3.33M | $2.92M | (m) | (m) | $323.87M | (m) |
| 2019-12-31 | (m) | (m) | $3.33M | $3.67M | (m) | (m) | $192.28M | (m) |
| 2019-09-30 | (m) | (m) | $3.33M | $4.40M | (m) | (m) | $186.99M | (m) |
| 2019-06-30 | (m) | (m) | $3.33M | $5.12M | (m) | (m) | $206.81M | (m) |
| 2019-03-31 | (m) | (m) | $3.33M | $5.83M | (m) | (m) | $140.17M | (m) |
| 2018-12-31 | (m) | (m) | $3.33M | $6.53M | (m) | (m) | $164.45M | (m) |
| 2018-09-30 | (m) | (m) | $2.50M | $7.22M | (m) | (m) | $115.79M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |